البيانات الاساسيه

السيره الذاتيه

C.V.

Heba Farouk Salem

Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy

The University of Beni –Suef, Egypt

Tel/ 002-01001944381

Name: Heba Farouk Salem

Date of Birth: 25/12/1971

Nationality: Egyptian

Address: 6 October City, Third district, fourth neighbourhood.

Education:

1989-1994 BSC. Of Pharmacy and Pharmaceutical sciences,

Faculty of Pharmacy, Cairo University, Egypt.

2000-2004 PhD of Pharmaceutical Nanotechnology and gene delivery using self assembled nanoparticles

School of Pharmacy, the University of Nottingham, UK .

2000-2005 Additional courses of marking and assessments, teaching, team work management, statistical analysis, philosophy of science , word for long document, scientific ethics, research management in science and engineering, building a bibliography, power point for presentation, developing data base with access-skills improvement, introduction to SPSS, data formatting and analysis with MS Excel and skills of spoken and written communications.

2005-2011 Advanced courses in teaching and communication skills by the FLDP.

2015 C++ programming, GIMP for editing by the university of Nottingham staff development courses

Position Held

2016 Professor of Pharmaceutics and industrial Pharmacy, the University of Beni-Suef.

2015-2016 Vice-dean of social services and environmental affairs. Faculty of Pharmacy, the University of Beni- Suef, Egypt.

Spring 2015 Visiting professor at the University of Nottingham, UK

2012-2014 Vice dean for higher education and research, The University of Beni-Suef, Egypt.

2011-2012 Vice-dean of social services and environmental affairs. Faculty of Pharmacy, the University of Beni- Suef, Egypt.

2011-2014 Head of Pharmaceutics and Industrial Pharmacy department, Faculty of Pharmacy. The University of Beni- Suef, Egypt.

2011-2012 Associate professor of Pharmaceutical Nanotechnology, The University of Beni- Suef, Egypt.

2005-2010 Assistant professors of Pharmaceutics and Industrial Pharmacy

Faculty of Pharmacy, The University of Beni- Suef, Egypt.

2008-2012 Assistant professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Nahda University ,Beni- Suef, Egypt.

2005-2010 Coordinator of the cultural affairs within school of Pharmacy the University of Beni-Suef

2007-2008 Consultant within the quality assurance unit

Faculty of pharmacy, the University of Beni-Suef.

2007-2008 Member of the research committee,

Faculty of pharmacy, the University of Beni-Suef.

1994-2000 Researcher in Drug Bioavailability Centre,

National Organisation for Drug Control and Research

(NODCAR), Egypt.

2005 Assistant professors of pharmaceutics and industrial pharmacy, Faculty of pharmacy, the University of Beni- Suef, Egypt.

2008-2011 Assistant professor of pharmaceutics and industrial pharmacy, Faculty of pharmacy, Nahda University ,Beni- Suef, Egypt.

2008-2009 Assistant professor of Pharmaceutics in ACU ( Al-ahram Canadian university)

2007-2008 Consultant within the quality assurance unit

Faculty of pharmacy, the University of Beni-Suef

2007-2008 Member of the research committee

Faculty of pharmacy, the University of Beni-Suef

1994-2000 Researcher in Drug Bioavailability Centre

National Organisation for Drug Control and Research

(NODCAR), Egypt.

Teaching Experience

Extensive participation in teaching the following subjects:

Physical pharmacy, community pharmacy, pharmaceutics 2 (solid dosage forms), pharmaceutics 3(parenterals), controlled release dosage forms, radiopharmacy, orientation, pharmacokinetics and biopharmaceutics, cosmetics, advanced drug delivery and history of pharmacy.

Area of Research Interest

My research interest is focused on designing non-viral gene delivery systems, biodegradable naoparticles (solid lipid naoparticles, nanocarriers for macromolecules and biologically active compounds. Targeted nanoparticles using different targeting moieties such as folic acid and folinic acid... etc,

I T Skills

Excellent experience in word, excel and power point and in using other soft wares such as winmd for analysis of flowcytometry results and WinNonlin for pharmacokinetic data analysis. Mini Tab for data mining and experimental design.

Other knowledge Very good experience in statistics especially the parametric tests using softwares such as prism.

Societies: Member of controlled release society (USA)

Member of British pharmaceutical society (UK)

Member of the Egyptian society of biomaterial science

Member of the Egyptian pharmaceutical society (Egypt)

Member of the Egyptian society of nanotechnology

Publications

Abdelbary AA, Salem HF and KhallafRA. Niosomal 5-Flourouracil gel for effective treatment of skin cancer; In-vitro and In-vivo evaluation. International journal of Drug delivery.( 2016) Accepted

Salem HF , Kharshoum RM , Abdel Hakim LF & Abdelrahim M E. Edge activators and a polycationic polymer enhance the formulation of porous voriconazole nano-agglomerate for the use as a dry powder inhaler. Journal of Liposome Research. Early Online: 1–12.2016

Salem HF, Sayed MA. and Omar MM. Liposomal flucytosine capped with gold nanoparticle formulations for improved. Drug Design, Development and Therapy 2016(10) 277–295

Maher EM, Ali AA, Salem HF, Abdeelbary AA. In vitro/in vivo evaluation of an optimized fast dissolving oral film containing olanzapine co-amorphous dispersion with selected carboxylic acids. Drug Deliv, Early Online: 1–13

Raghda R. S. Hussein, Ahmed M. A. Ali, Heba F. Salem, Maha M. Abdelrahman, Amira S. A. Said & Mohamed E. A. Abdelrahim. In vitro/in vivo correlation and modeling of emitted dose and lung deposition of inhaled salbutamol from metered dose inhalers with different types of spacers in noninvasively ventilated patients. Pharmaceutical Development and Technology, Early Online: 1–10. 2015 DOI: 10.3109/10837450.2015.1116567

Salem HF, Sayed MA. Hassaballah A S and Omar MM. Targeting Brain Cells with Glutathione -Modulated Nanolipsosomes: in vitro and in vivo study. Drug Design, Development and Therapy. 2015 (9) 1-23.

Ali MF, Salem HF, Abdelmohsen H, Atteia S K. Preparation and clinical evaluation of nano-transferosomes for treatment of erectile dysfunction. Drug Design, Development and Therapy. 2015 (9) 2431-2447.

Abdelrahman AA, Salem HF, Khallaf R A, and Abdelhaleem AA. “Modeling, Optimization, and In Vitro Corneal Permeation of Chitosan-Lomefloxacin HCl Nanosuspension Intended for Ophthalmic Delivery,” Journal of Pharmaceutical Innovation, 2015.

AM Abou-Yousef, Salem HF, MA Hamzawy . Alternative Animal model of urethane induced lung cancer: a pilot study. Toxicology Letters, 2014

Salama H, Zekri A, Salem HF, Omran D, Abd elrahman M. Comparative Efficacy of Amantadine hydrochloride Against The efficacy of amantadine sulfate in treating Egyptian patients with chronic HCV. International journal of tropical disease and health. 2014 (4) 10 11-4-1010.

Salem H F, Ahmed S M, Omar M M. ^.Computed tomography imaging of nanotheranostics iiposoms for ocular delivery. Proceeding of controlled release conference. 2014

Kharshoum RM , Salem HF. Formulation and Evaluation of Ketotifen Fumarate Fast Disintegrating Sublingual Tablets. Int J Drug Deliv. 2011; 3 : 619-632

Salem HF, Abdelrahim ME, Eid KA, Sharaf MA. Nanosized rods agglomerates as a new approach for formulation of a dry powder inhaler. Int J Nanomedicine. 2011; 6:311-20.

Salem HF, Sustained-release of progesterone nanosuspension following Intramuscular Injection in ovariectomised rats. Int J Nanomedicine. 2010; 5:943-54.

Salem HF, Fahmy ,Ali AM. Extended immunization of rats using microencapsulated Cobra venom. Br. J Pharm and Toxic. 2011;1: 43-50, 2011

Abd Elbary A, Salem HF , Maher EM. In vitro and in vivo evaluation of glibenclamide using surface solid dispersion (SSD) Approach. Br. J Pharm and Toxic . 2011; 1: 51-62.

Salem HF, Eid KA, Sharaf MA. Formulation and evaluation of silver nanoparticles as antibacterial and antifungal agents with a minimal cytotoxic effect. Int J Drug Deliv. 2011; 3 : 293-304

Abd El-Bary AA, Salem HF, Kharshoum RM .2-Hydroxypropyl-ß-Cyclodextrin Complex with Ketotifen Fumerate for eye drops preparations. Int J Drug Deliv. 2011;3 : 228-240

Salem HF, Abdelrahim ME, Abo Eid K, Sharaf MA, Agglomeration of theophylline Nanoparticles: a New Protocol for Pulmonary Drugs Administration, oral presentation in The XXVIII international conference 2010 on Solid State Science and Materials Physics & workshop on Functional Nanostructures and Hybrid Organic-Inorganic Materials, Fayoum, Egypt (March 22^nd-25^th), Conference book 2010.

Salem HF, R Khalaf, Abd Elbary AA, Incorporation of the chemotherapeutic agent 5-fluorouracil into solid lipid nanoparticles for topical application: Production, Characterization and release oral presentation in The XXVIII international conference 2010 on Solid State Science and Materials Physics & workshop on Functional Nanostructures and Hybrid Organic-Inorganic Materials, Fayoum, Egypt (March 22^nd-25^th), Conference book 2010.

Abd Elbary A, Salem HF, Maher E., Using solvent deposition techniques to enhance solubility of glibenclamide, proceedings of the Egypt. Pharmace. Soci. Egypt.2008; p-30

El-Tantawy WH. Salem HF. ,Safwat NM. , Effect of Fascioliasis on the Pharmacokinetics Parameter of Triclabendazole in human Subjects. J Pharm. world Sci. 2007;3:190-8

El Said MY., Salem HF, Moharram SE. , A Study of the Effect of Different Semisolid Bases on the Sustainment of Local Activity of Econazole Nitrate. Proceeding of the Egypt. Pharmace.Soci., Dec. Egypt .2006; p-1.

EL-Tantawy WH, Salem HF, Clinical pharmacokinetics study of Two Trichlabendazole Formulations in Patients with Fascioliasis, Boll. Chem. Farm. 2005; 5:67-75

Salem HF., Stolnik S., Garnett MC. Physicochemical, Binding and Cellular Uptake of Folinate Modified Macromolecules and Gene Delivery System. J. pharm and pharm.2003; S-13

Salem HF, Bignotti F , Lee R. , Stolnik S. , Garnett M. Sterically Stabilised Gene Delivery Systems Incorporating Targeting Ligand and Amphipathic Peptides. Proceeding of The Controlled release 30^th annual meeting.2003; p-627

Salem HF, Stolnik S, Garnett MC. Incorporation of Targeting Moiety into a Multicomponent DNA delivery system. J. Pharm. and pharm. 2002; S60-61

Conferences and Visits

2015 Visiting professor in the university of Nottingham UK

2014 Computed tomography imaging of nanotheranostics liposomes for ocular delivery. controlled release conference USA . 2014

2013 Invited speaker in nanotechnology for applied sciences. One day workshop 2013. Cairo, Egypt.

2012 Invited speaker in ABAS 1. The international conference of applied biological analysis and sciences, Hurghada, Egypt.

2010 Invited speaker in Nanotech Egypt (September 18-22, 2010)

2010 invited speaker in XXVIII international conference 2010 on Solid State Science and Materials Physics & workshop on Functional Nanostructures and Hybrid Organic-Inorganic Materials, Fayoum, Egypt (March 22^nd-25^th), Conference book 2010.

2010 invited speaker in nanotechnology workshop The University of Beni Suef 28 Feb (2010)

2009 nanotechnology and its application, the national research institute, Cairo, Egypt

2008 31^st International conference of the Egyptian pharmaceutical society, Egypt

2006 30^tyInternational conference of pharmaceutical sciences, Cairo, Egypt

2005 2^nd international conference of scientific research and its application, Cairo, Egypt.

2003 British pharmaceutical conference, Harrogate, UK.

2003 Controlled release society conference, Glasgow, UK.

2002 British pharmaceutical conference, Manchester, UK.

2001 British pharmaceutical conference, Glasgow, UK.

Projects Principal investigator of STDF project (ID 1636 ) “formulation and evalauation of self assembled siRNA nanocarriers for the possible treatment of HCV”. Final budget one million 1 000.000 LE

Awards:

2012-March The University award in the First science day

2008-2009. Final selection in the Islamic development bank award as a post doctoral fellow, USA.

Contact details: heba_salem2004@yahoo.co.uk, Tel /0100194438

References:

1-Prof. Martin Garnett, Professor in advanced drug delivery and tissue engineering group, School of pharmacy , the University of Nottingham, NG7 2RD, UK

e.mail: m.garnett@nottingham.ac.uk

2- . Abdel-Rahman N.Zekri M.Sc., Ph.D Prof. Molecular Virology and Immunology Head of Molecular Virology and Immunology . Head of Human Genetic Center Cancer Biology Department, National Cancer Institute

ncizekri@yahoo.com

2-Prof. Dr. Abdallah Molokhia, Chairman of European Egyptian Pharmaceutical

Company, Alexandria, Egypt.

نسخه للتحميل

عنوان رسالة الماجستير

formulation of multi components DNA delivery system to incorporate a targeting moiety

ملخص رسالة الماجستير

ABSTRACT Polyamidoamine cationic polymers with DNA have potential as non-viral gene delivery systems. However, they have poor in vivo distribution and a tendency to aggregate. This can be overcome by the use of homo/copolymer blends to form multicomponent DNA delivery systems (MCDS). Multicomponent DNA delivery systems have been proven to have poor transfection efficiency in vitro (Rackstraw et al 2002). Therefore, the aim of this study was to improve the uptake of the multicomponent DNA delivery systems by incorporating a targeting moiety. Folinic acid, as a novel-targeting moiety, was suggested for this work. Formulation and screening studies for the best ratio/s of multicomponent DNA delivery systems were investigated. This was carried out using DNA with different blends of polyamidoamine homo/copolymer (MBA-DMEDA and PEGylated MBA-DMEDA, which are referred to by their batch numbers NG52 and NG54 respectively). Homo/copolymers at (2:1) and (3:1) ratios proved to have the best collective physicochemical characteristics among all of the investigated series. The investigation was carried out using ethidium-bromide (Et-Br) displacement assay, gel electrophoresis, photon correlation spectroscopy (PCS) and transmission electron microscopy (TEM). Folinic acid-PEG-PAA-PEG-folinic and folic acid-PEG-PAA-PEG-folic acid conjugates were synthesised using the water-soluble carbodiimide coupling agent (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide). The final molar substitution ratios (MSR) were 2:1 of folinic acid to polymer and 1.9:1 of folic acid to polymer. The physicochemical characteristics of both folinic acid and folic acid modified complexes with DNA were then investigated. The results showed no significant differences between folinic acid modified particles and the non-modified ones. However, there was a significant difference between folic acid modified particles and the non-modified ones. Studying of the binding and the uptake of folinic and folic acid-BSA conjugates on a 791T osteosarcoma cell line were investigated. The binding of this targeting moiety could be inhibited by the presence of free folinic acid and its conjugate but not with free folic acid, which showed the specificity to this ligand. Folinic-BSA conjugates were also endocytosed by cells through non-clathrin mediated pathway. These results showed the ability of folinic acid to work as a targeting moiety with potential in vivo advantages. In the last chapter three main topics were investigated. The first topic was to compare the transfection of NG52/54–folinic acid modified nanoparticles with both folic acid modified and the non-modified nanoparticles. The results showed the ability of folinic acid to improve the transfection of the polymer blend 40–200 times relative to a non-modified system. At the same time folinic acid modified complexes have a transfection activity similar to that of folic acid complexes. The second topic was qualitative and quantitative investigation of DNA complex trafficking using YO YO dye. The results showed the ability of folinic acid complexes to be taken by the cells faster and to a higher level than that of folic acid and the homopolymer on its own. The third topic was the in vivo assessment of the complexes. This was carried out by comparing the pharmacokinetics, biodistribution and the transfection of folinic acid, folic acid and the non-modified nano-particles, which showed no difference in the examined parameters of the systems studied. This might be attributed to the instability of the complexes in serum. The initial aims of the project have therefore been accomplished. A ligand has been incorporated resulting in enhanced uptake and transfection activity. Folinic acid was validated as a suitable targeting moiety in vitro showing appropriate specificity and uptake.

ملخص الرساله PDF

عنوان رسالة الدكتوراه